PubMed:27319011 JSONTXT

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":136,"end":160},"obj":"DP"},{"id":"T10","span":{"begin":1429,"end":1441},"obj":"CI"},{"id":"T11","span":{"begin":1705,"end":1717},"obj":"CI"},{"id":"T12","span":{"begin":837,"end":846},"obj":"CI"},{"id":"T13","span":{"begin":1569,"end":1578},"obj":"CI"},{"id":"T15","span":{"begin":1130,"end":1142},"obj":"CI"},{"id":"T16","span":{"begin":110,"end":122},"obj":"CI"},{"id":"T17","span":{"begin":883,"end":890},"obj":"CI"},{"id":"T18","span":{"begin":816,"end":823},"obj":"CI"},{"id":"T19","span":{"begin":1202,"end":1209},"obj":"CI"},{"id":"T2","span":{"begin":314,"end":338},"obj":"DP"},{"id":"T3","span":{"begin":340,"end":344},"obj":"DP"},{"id":"T4","span":{"begin":639,"end":643},"obj":"DP"},{"id":"T5","span":{"begin":1535,"end":1539},"obj":"DP"},{"id":"T6","span":{"begin":796,"end":808},"obj":"CI"},{"id":"T7","span":{"begin":525,"end":537},"obj":"CI"},{"id":"T8","span":{"begin":756,"end":768},"obj":"CI"},{"id":"T9","span":{"begin":863,"end":875},"obj":"CI"},{"id":"T20","span":{"begin":924,"end":933},"obj":"CI"}],"text":"Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.\nINTRODUCTION: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM.\nMETHODS: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.\nRESULTS: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P \u003c 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P \u003c 0.00001) and HbA1c (P \u003c 0.00001).\nCONCLUSION: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide.\nFUNDING: Sanofi.\nCLINICAL TRIAL NUMBERS: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S)."}

{"project":"yangbin123xm_800_3","denotations":[{"id":"T10","span":{"begin":796,"end":808},"obj":"CI"},{"id":"T11","span":{"begin":1130,"end":1142},"obj":"CI"},{"id":"T12","span":{"begin":1429,"end":1441},"obj":"CI"},{"id":"T13","span":{"begin":1705,"end":1717},"obj":"CI"},{"id":"T14","span":{"begin":136,"end":160},"obj":"DP"},{"id":"T15","span":{"begin":314,"end":338},"obj":"DP"},{"id":"T16","span":{"begin":837,"end":846},"obj":"CI"},{"id":"T17","span":{"begin":1569,"end":1578},"obj":"CI"},{"id":"T18","span":{"begin":883,"end":890},"obj":"CI"},{"id":"T19","span":{"begin":816,"end":823},"obj":"CI"},{"id":"T20","span":{"begin":1202,"end":1209},"obj":"CI"},{"id":"T3","span":{"begin":340,"end":344},"obj":"DP"},{"id":"T4","span":{"begin":639,"end":643},"obj":"DP"},{"id":"T5","span":{"begin":1535,"end":1539},"obj":"DP"},{"id":"T6","span":{"begin":110,"end":122},"obj":"CI"},{"id":"T7","span":{"begin":525,"end":537},"obj":"CI"},{"id":"T8","span":{"begin":756,"end":768},"obj":"CI"},{"id":"T9","span":{"begin":863,"end":875},"obj":"CI"},{"id":"T21","span":{"begin":924,"end":933},"obj":"CI"}],"text":"Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.\nINTRODUCTION: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM.\nMETHODS: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c.\nRESULTS: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P \u003c 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P \u003c 0.00001) and HbA1c (P \u003c 0.00001).\nCONCLUSION: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide.\nFUNDING: Sanofi.\nCLINICAL TRIAL NUMBERS: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S)."}